The gold compound auranofin induces apoptosis of human multiple myeloma cells through both down-regulation of STAT3 and inhibition of NF-κB activity

Leukemia Research

Volumn 35, Issue 2, 2011, Pages 243-249

  Nakaya, Aya ^a   Sagawa, Morihiko ^b   Muto, Akihiro ^c   Uchida, Hideo ^d   Ikeda, Yasuo ^a   Kizaki, Masahiro ^b  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c HOSHI UNIVERSITY   (Japan)

^d TOKYO ELECTRIC POWER COMPANY   (Japan)

Author keywords

Apoptosis; Auranofin; IL 6; JAK STAT; Mcl 1; Multiple myeloma; NF B

Indexed keywords

AURANOFIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; JANUS KINASE 2; PROTEIN MCL 1; STAT3 PROTEIN;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL GROWTH; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; AURANOFIN; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMANS; MULTIPLE MYELOMA; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANSFECTION;

EID: 78751705649     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.05.011     Document Type: Article

References (50)

1. Hideshima T., Anderson K.C. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002, 2:927-937.
2. Weber D. Thalidomide and its derivatives: new promise for multiple myeloma. Cancer Control 2003, 10:375-383.
3. Yasui H., Hideshima T., Richardson P.G., Anderson K.C. Recent advances in the treatment of multiple myeloma. Curr Pharm Biotechnol 2006, 7:381-393.
4. Chng W.J., Tan L.H. Targeted therapy in multiple myeloma. Cancer Control 2005, 12:91-104.
5. Ocio E.M., Mateos M.V., Maiso P., Pandiella A., San-Miguel J.F. New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. Lancet Oncol 2008, 9:1157-1165.
6. Hideshima T., Bergsagel P.L., Kuehl W.M., Anderson K.C. Advances in biology of multiple myeloma: clinical applications. Blood 2004, 104:607-618.
7. Miyakoshi S., Kami M., Yuji K., Matsumura T., Takatoku M., Sasaki M., Narimatsu H., Fujii T., Kawabata M., Taniguchi S., Ozawa K., Oshimi K. Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood 2006, 107:3492-3494.
8. Feinman R., Koury J., Thames M., Barlogie B., Epstein J., Siegel D.S. Roles of NF-κB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. Blood 1999, 93:3044-3052.
9. Ni H., Ergin M., Huang Q., Qin J.Z., Amin H.M., Martinez R.L., Saeed S., Barton K., Alkan S. Analysis of expression of nuclear factor-κB (NF-κB) in multiple myeloma; downregulation of NF-κB induces apoptosis. Br J Haematol 2001, 115:279-286.
10. Catlett-Falcone R., Landowski T.H., Oshiro M.M., Turkson J., Levitzki A., Savino R., Ciliberto G., Moscinski L., Fernandez-Luna J.L., Nunez G., Dalton W.S., Jove R. Constitutive Activation of Stat3 Signaling Confers Resistance to Apoptosis in Human U266 Myeloma Cells. Immunity 1999, 10:105-115.
11. Bharti A.C., Shishodia S., Reuben J.M., Weber D., Alexanian R., Raj-Vadhan S., Estov Z., Talpaz M., Aggarwal B.B. Nuclear factor-κB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 2004, 103:3175-3184.
12. Bharti A.C., Donato N., Aggarwal B.B. Curcumin (diferuloymethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 2003, 171:3863-3871.
13. Yamada R., Sano H., Hla T., Hashiramoto A., Fukui W., Miyazaki S., Kohno M., Tsubouchi Y., Kusaka Y., Kondo M. Auranofin inhibits interleukin-1 β-induced transcript of cyclooxygenase-2 on cultured human synoviocytes. Eur J Pharmacol 1999, 385:71-79.
14. Jeon K.I., Jeong J.Y., Jue D.M. Thiol-reactive metal compounds inhibit NF-κB activation by blocking IκB kinase. J Immunol 2000, 164:5981-5989.
15. Jeon K.I., Byun M.S., Jue D.M. Gold compound auranofin inhibits IκB kinase (IKK) by modifying Cys-179 of IKKβ subunit. Exp Mol Med 2003, 35:61-66.
16. Collier D.S., Grant R.W., Estey G., Surrao D., Chueh H.C., Kay J. Physician ability to assess rheumatoid arthritis disease activity using an electronic medical record-based disease activity calculator. Arthritis Rheum 2009, 61:495-500.
17. Gromer S., Arscott L.D., Williams J.R.C.H., Schirmer R.H., Becker K. Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhabitation by therapeutic gold compounds. J Biol Chem 1998, 273:20096-20101.
18. Rigobello M.P., Scutari G., Boscolo R., Bindoli A. Induction of mitochondria permeability transition by auranofin, a gold (I)-phosphine derivative. Br J Pharmacol 2002, 136:1162-1168.
19. McKeage M.J. Gold opens mitochondrial pathways to apoptosis. Br J Pharmacol 2002, 136:1081-1082.
20. Rigobello M.P., Scutari G., Folda A., Bindoli A. Mitochondrial thioredoxin reductase inhibition by gold (I) compounds and concurrent stimulation of permeability transition and release of cytochrome c. Biochem Pharmacol 2004, 67:689-696.
21. Green D.R. Apoptotic pathway: the roads to ruin. Cell 1998, 94:695-698.
22. Kim I.S., Jin J.Y., Lee I.H., Park S.J. Auranofin induces apoptosis and when combined with retinoid acid enhances differentiation of acute promyelocytic leukemia cells in vitro. Br J Pharmacol 2004, 142:749-755.
23. Park S.J., Kim I.S. The role of p38 MAPK activation in auranofin-induced apoptosis or human promyelocytic leukemia HL-60 cells. Br J Phamacol 2005, 146:506-513.
24. Kawano M., Hirano T., Matsuda T., Taga T., Hori Y., Iwato K., Asaoku H., Tang B., Tanabe O., Tanaka H., Kuramoto A., Kishimoto T. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988, 332:83-85.
25. Ogata A., Chauhan D., Teoh G., Treon S.P., Urashima M., Schlossman R.L., Anderson K.C. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol 1997, 159:2212-2221.
26. Hsu J.H., Shi Y., Hu L., Fisher M., Franke T.F., Lichtenstein A. Role of the AKT kinase in expansion of multiple myeloma clones: effects on cytokine-dependent proliferative and survival responses. Oncogene 2002, 21:1391-1400.
27. Chauhan D., Pandey P., Hideshima T., Treon S., Raje N., Davies F.E., Shima Y., Tai Y.-T., Rosen S., Avraham S., Kharbanda S., Anderson K.C. SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. J Biol Chem 2000, 275:27845-27850.
28. Puthier D., Bataille R., Amiot M. IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than Ras/MAP kinase pathway. Eur J Immunol 1999, 29:3945-3950.
29. Puthier D., Derenne S., Barille S., Moreau P., Harousseau J., Batalle R., Amiot M. Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells. Br J Haematol 1999, 107:392-395.
30. Shirogane T., Fukuda T., Muller J.M., Shima D.T., Hibi M., Hirano T. Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis. Immunity 1999, 11:709-719.
31. Kozopas K.M., Yang T., Buchan H.L., Zhou P., Craig R.W., MCL-1 a gene expressed in programmed myeloid cell differentiation, has sequence similarity to Bcl-2. Proc Natl Acad Sci USA 1993, 90:3516-3520.
32. Gomez-Bougie P., Bataille R., Amiot M. The imbalance between Bim and Mcl-1 expression controls the survival of human myeloma cells. Eur J Immunol 2004, 34:3156-3164.
33. Le Gouill S., Podar K., Harousseau J.L., Anderson K.C. Mcl-1 regulation and its role in multiple myeloma. Cell Cycle 2004, 3:1259-1262.
34. Siebenlist U., Brown K., Claudio E. Control of lymphocyte development by nuclear factor-κB. Nat Rev Immunol 2005, 5:435-445.
35. Richardson P.G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., Rajkumar S.V., Srkalovic G., Alsina M., Alexanian R., Siegal D., Orlowski R.Z., Kuter D., Limentani S.A., Lee S., Hideshima T., Esseltine D.L., Kauffman M., Adams J., Schenkein D.P., Anderson K.C. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Eng J Med 2003, 348:2609-2617.
36. Richardson P.G., Schlossman R.L., Weller E., Hideshima T., Mitsiades C., Davies F., LeBlanc R., Catley L.P., Doss D., Kelly K., McKenney M., Mechlowicz J., Freeman A., Deocampo R., Rich R., Ryoo J.J., Chauhan D., Balinski K., Zeldis J., Anderson K.C. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002, 100:3063-3067.
37. Sen R. Control of B lymphocyte apoptosis by the transcription factor NF-κB. Immunity 2006, 25:871-883.
38. Okita H., Umezawa A., Suzuki A., Hata J. Up-regulated expression of murine Mcl1/EAT, a bcl-2 related gene, in the early stage of differentiation of murine embryonal carcinoma cells and embryonic stem cells. Biochem Biophys Acta 1998, 1398:335-341.
39. Cotter T.G. Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer 2009, 9:501-507.
40. Thorburn A. Death receptor-induced cell killing. Cell Signal 2004, 16:139-144.
41. Hengartner M.O. The biochemistry of apoptosis. Nature 2000, 407:770-776.
42. Marchetti P., Castedo M., Susin S.A., Zamzami N., Hirsch T., Macho A., Haefner A., Hirsch F., Geuskens M., Kroemer G. Mitochondrial permeability transition is a central coordinating event of apoptosis. J Exp Med 1996, 184:1155-1160.
43. Du C., Fang M., Li Y., Li L., Wang X., Smac a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000, 102:33-42.
44. Verhagen A.M., Eker P.G., Pakusch M., Silke J., Connolly L.M., Reid G.E., Moritz R.L., Simpson R.J., Vaux D.L. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000, 102:43-53.
45. Ito K., Nakazato T., Xian M.J., Yamada T., Hozumi N., Murakami A., Ohigashi H., Ikeda Y., Kizaki M. 1′-acetoxychavicol acetate is a novel nuclear factor κB inhibitor with significant activity against multiple myeloma in vitro and in vivo. Cancer Res 2005, 65:4417-4424.
46. Nakazato T., Ito K., Ikeda Y., Kizaki M. Green tea component, catechin, induces apoptosis of human malignant B cells via production of reactive oxygen species. Clin Cancer Res 2005, 11:6040-6049.
47. Shimizu T., Nakazato T., Xian M.J., Sagawa M., Ikeda Y., Kizaki M. Resveratrol induces apoptosis of human malignant B cells by activation of caspase-3 and 038 MAP kinase pathways. Biochem Pharmacol 2006, 71:742-750.
48. Sagawa M., Nakazato T., Uchida H., Ikeda Y., Kizaki M. Cantharidin induces apoptosis of human multiple myeloma cells via inhibition of the JAK/STAT pathway. Cancer Sci 2008, 99:1820-1826.
49. Dai Y., Pei X., Rahmani M., Conrad D.H., Dent P., Grant S. Interruption of the NF-κB pathway by Bay 11-7082 promotes UCN-01mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells. Blood 2004, 103:2761-2770.
50. Sanders M. A review of controlled clinical trials examining the effects of antimalarial compounds and gold compounds on radiographic progression in rheumatoid arthritis. J Rheumatol 2000, 27:523-529.